Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, longitudinal, uncontrolled study with follow-up for 5 years.Patients
having undergone surgical excision of lentigo maligna (LM) or lentigo maligna melanoma (LMM)
will be invited to this study. Eligible patients will start treatment with imiquimod 6 weeks
after the excision, the treatment will last for up to 12 weeks. Inflammatory reactions and
the occurrence of residual lesions will be documented. The healing effect will be determined
(initial clearance rate) 20 weeks after start of treatment with imiquimod. All patients who
were enrolled (=exposed to imiquimod in this study) will be followed up for 5 years or until
recurrence of the LM or LMM